| Document |
Document Title |
|
JP2012515799A |
or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, ...
|
|
JP4965489B2 |
Cationic lipids having a derivatized quaternary ammonium head group that provide improved cell targeting ability and enhanced transfective efficacy for introducing molecules into cells are provided.
|
|
JP4956182B2 |
Compounds of formula (Ia): wherein R 1 , R 2 , R 3 , R 4a , R 4b , R 5 and R 6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the co...
|
|
JP4955659B2 |
The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as a plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, can be effectively used in delivering ...
|
|
JP2012107045A |
To provide novel 9-substituted minocycline compounds.The novel 9-substituted minocycline compound is expressed by the following formula. A region of naphthylthiourea can be various substituents such as phenylurea and phenylsulfone amide....
|
|
JP4949206B2 |
|
|
JP2012102130A |
To provide a compound useful for therapeutic measures of nervous disease such as insult, head injury, spinal damage, epilepsia and anxiety or nerve disorder, neurodegenerative disease such as Alzheimer's dementia, Huntington's disease or...
|
|
JP4925549B2 |
The present invention pertains, at least in part, to novel 9- substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasm...
|
|
JP4922924B2 |
Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compo...
|
|
JP4915019B2 |
Disclosed is an alanine racemase chiral binaphthol derivative having the ability to recognize amino alcohols selectively on the basis of chirality and transform amino acids from an L-form into a D-form. Methods for the optical resolution...
|
|
JP4911820B2 |
|
|
JP2012507552A |
The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.
|
|
JP4903921B2 |
The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin alpha v beta 5 antagonists. The alpha v beta 5-mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial...
|
|
JP2012046525A |
To provide a compound and method useful in modulating angiogenesis, and to provide a method of treating or preventing a disease or disorder associated with angiogenesis by administering a polycationic compound.There is provided a salicyl...
|
|
JPWO2010024225A1 |
The following general formula (1) useful as a disinfectant / disinfectant[In the formula, R1Indicates a hydrogen atom, an optionally substituted alkyl group, etc., and R2Indicates a hydrogen atom or an optionally substituted alkyl group,...
|
|
JP2012012376A |
To provide a medical agent which possesses an excellent inhibitory effect on NHE3 (Na+/H+ exchanger type 3) and effectively improves diseases of organs in which NHE3 is expressed.There is provided and used the new acylguanidine derivativ...
|
|
JP4854853B2 |
Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having general structure (A):
|
|
JP4855368B2 |
The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases m...
|
|
JP4846238B2 |
One aspect of the present invention relates to a method of purifying radiolabelled compounds comprising a) loading onto a fluorous polymer a radiolabelled compound precursor comprising a fluoroalkyl tin moiety; b) reacting the radiolabel...
|
|
JP4847875B2 |
A method of preparing salt of dinitramidic acid, comprising nitration of an initial compound with a nitrating acid mixture to form dinitramidic acid in a reaction mixture. A positive ion is added to the reaction mixture and forms with th...
|
|
JP4833394B2 |
Cosmetic slimming composition comprises a compound (I) selected from L-arginine and its analogs, derivatives and salts and an excipient. Cosmetic slimming composition comprises a compound of formula (I) and an excipient: R1 = H, OH, acyl...
|
|
JP2011528741A |
The present invention provides a mixture comprising at least three hardener components a1), a2), and b), the ratio of hardener component a1) to a2) being in the range from 0.1 to 10:1, and hardener component b) being present at 5% to 55%...
|
|
JP2011528743A |
The present invention provides a blend comprising one or more epoxy resins and a mixture which comprises 0.3 to 0.9 amine equivalent, per equivalent of epoxide of the epoxy resin used, of a hardener component a) and as hardener component...
|
|
JP4785315B2 |
A family of borate compounds containing an isolated (finite) nonaborate anion with the structural formula [B9O12(OH)6]3-. Preferred amine nonaborate compounds have a resolved oxide formula of A2O.3B2O3.2H2O, where A is the monovalent cat...
|
|
JPWO2009142204A1 |
To provide an amino acid generator in which a protective group of an amino group is removed to generate an amino acid, and a film-forming composition using the amino acid generator and a polysiloxane composition containing the same. A fi...
|
|
JP2011525515A |
The invention relates to ether guanidines of the general formulae (I) and/or salts or hydrates thereof, in which R1=-CH2-CH2-CH2-O-R3 where R3 is, independently of the others, hydrocarbon radicals having greater than or equal to 10 carbo...
|
|
JP4758584B2 |
The invention relates to a method for producing 1-methyl-3-nitroguanidine. According to said method, nitroguanidine is reacted with methylamine and/or a methylammonium salt in an aqueous solution, at temperatures of 30 to 60° C. and at ...
|
|
JP4755211B2 |
Aqueous solutions of hexasubstituted guanidinium chlorides are prepared from phosgene and secondary amines. The solutions may be employed as sources of hexasubstituted guanidinium salts useful as phase transfer catalysts and the reaction...
|
|
JP4754071B2 |
A composition comprising a polymer containing a compound represented by Formula (1) or a salt thereof as a constituent monomer, or a polymer containing a structure represented by Formula (9) as a partial structure is used for protecting ...
|
|
JP2011520962A |
Provided herein are novel cationic lipids, compositions comprising the cationic lipids, and methods of using the cationic lipids. In some claims, the cationic lipids have cytotoxic activity and can be used alone or in combination with a ...
|
|
JP4723526B2 |
An alditol or inositol-based derivative is provided to be used as a transporter for various molecules having excellent biomembrane permeability and biological activity. A sugar-alcohol derivative or salt thereof has a structure represent...
|
|
JP2011121966A |
To provide cationic lipids and compositions of the cationic lipids having utility in lipid aggregates for delivery of macromolecules and other materials into cells.There are provided compounds expressed by general structural formula. The...
|
|
JP4700880B2 |
The present invention relates to a novel process for the preparation of N-methyl-N'-nitroguanidine by reacting nitroguanidine with aqueous methylamine solution buffered by the addition of inorganic or organic acids.
|
|
JP4698773B2 |
The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and...
|
|
JP4690345B2 |
The present invention relates to a two-step process for the preparation of guanidinium salts of the formula (1), where the substituents R have a meaning indicated in Claim, and A- is a sulfonate, alkyl- or arylsulfate, hydrogensulfate, i...
|
|
JP2011509074A |
Substituted ester compounds (I) and their acid addition salts are new. Substituted ester compounds of formula (R-(E) m-(AA) n-[(W 1-L-W 2) p-(Y 2) q-(Z) r] s) (I) and their acid addition salts are new. R : lipophilic group (comprising on...
|
|
JP4658430B2 |
The present invention relates to compounds of the formula I, in which A, L, Y and k have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithro...
|
|
JP4621426B2 |
A method for treating a cytotoxic disease by administrating compounds having a general formula X-(A)n-Y, wherein: n varies between 6 and 20; X denotes a hydrogen atom, an RaCO, RaOCO, RaNHCO or RaSO2 group, Ra being an alkyl, alkenyl, al...
|
|
JP2011500656A |
This invention relates to cationic lipids. More particularly the invention relates to biodegradable cationic lipids having a plurality of cationic headgroups and one or more lipophilic tail groups. The lipids are of utility in various ap...
|
|
JP4602991B2 |
Inositol derivatives in accordance with the present invention are effective in significantly enhancing the transportation of various therapeutic molecules across a biological membrane, which may include the plasma membrane, nuclear membr...
|
|
JP4598397B2 |
Novel cycloalkyl compounds useful as inhibitors of potassium channel function (especially inhibitors of the K v l subfamily of voltage gated K + channels, especially inhibitors K v 1.5 which has been linked to the ultra-rapidly activatin...
|
|
JP4596793B2 |
|
|
JP4597237B2 |
The invention relates to a process for preparing substituted cyclopentane derivatives represented by the formula (I)wherein R1, R2, R3, R4, X and Y are as described in the specification, and pharmaceutically acceptable salts thereof.The ...
|
|
JP4588951B2 |
Method of producing compounds of formula (I), wherein R1 is hydrogen or C1-C4-alkyl; R2 is hydrogen, C1-C8-alkyl, C3-C6-cycloalkyl, or a radical -N(R3)R4; or R2 and R6 together are -CH2-CH2-S-; R3 and R4 are hydrogen, C1-C4-alkyl, C3-C6-...
|
|
JP4573006B2 |
|
|
JP4567889B2 |
The invention to a pharmaceutical composition comprising as active principle a compound of general formula (I), in which R1, R2, R3, and A are as defined in claim 1. These compositions can be used in the treatment of pathologies associat...
|
|
JP4550286B2 |
Acylquanidines of the formulawherein the substituents are defined as in the specification which are antagonists of the vitronectin receptor and inhibitors of cell adhesion and bone resorption mediated by the osteoclasts.
|
|
JP4545911B2 |
|
|
JP4544639B2 |
The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin alpha v beta 5 antagonists. The alpha v beta 5-mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial...
|
|
JP2010195793A |
To provide a production method in which using of a protecting group or an expensive derivative is not needed, and which is suitable for composing amides of beta-alanine useful as a medicine like carcinine, and to provide a novel syntheti...
|
